

1
2
3
4

SUPPLEMENTAL MATERIAL

5 **PREDICTORS OF POOR OUTCOME DESPITE SUCCESSFUL**
6 **ENDOVASCULAR THROMBECTOMY FOR ISCHEMIC STROKE:**
7 **RESULTS FROM THE MR CLEAN REGISTRY**

8
9

1 **Supplemental methods**

2
3 In the evaluation of the added Chi² of the individual parameters, the sum of all
4 individual Chi² proportions can be below or above 1 and quantification measures
5 should be interpreted in context of the model. For example, if all independent
6 variables are perfectly identical (collinear), the model can have good performance,
7 but proportion Chi² for all independent variables will be zero, because any single
8 predictor has zero additional explanatory value. On the other hand, if all independent
9 variables together explain the dependent variable perfectly, proportion Chi² for each
10 predictor will be 1, because whatever is unexplained by all other predictors can
11 perfectly be explained by the remaining variable.

12

1
2

Table 1. Cohort characteristics and predictor clustering

	eTICI 2B, n=695	eTICI 2C, n=332	eTICI 3, n=886	Missing
<i>Patient factors</i>				
Age	69 (15)	69 (14)	70 (14)	0
Male sex	359 (52)	184 (55)	467 (53)	0
NIHSS on admission	15 [10, 19]	16 [11, 20]	16 [11, 20]	1.5
Ischemia in left hemisphere	382 (55)	177 (53)	460 (52)	0.6
Systolic blood pressure on admission	149 (25)	151 (25)	148 (24)	3.2
INR on admission	1.1 (0.4)	1.2 (0.4)	1.2 (0.4)	18
Glucose level on admission	7.4 (2.7)	7.4 (2.4)	7.4 (2.6)	11
Previous stroke	112 (16)	58 (18)	139 (16)	0.8
Atrial fibrillation	141 (21)	87 (26)	199 (23)	1.3
Hypertension	341 (51)	171 (52)	455 (52)	2.2
Diabetes mellitus	101 (15)	63 (19)	146 (17)	0.7
Pre-stroke mRS (%)				2.3
0 - No symptoms	457 (68)	229 (71)	594 (68)	
1 - Minor symptoms, no limitations	86 (13)	39 (12)	122 (14)	
2 - Slight disability, no help needed	45 (6.7)	30 (9.2)	60 (6.9)	
>2	88 (13)	27 (8.3)	92 (11)	
Prior antiplatelet therapy	204 (30)	112 (34)	285 (33)	1.4
Time from symptom onset to admission ER (intervention center)	133 [65, 186]	135 [60, 189]	130 [68, 181]	4.9
<i>Imaging factors</i>				
Occluded segment				3.8
Intracranial ICA	30 (4.5)	15 (4.7)	36 (4.2)	
ICA-T	127 (19)	73 (23)	166 (19)	
M1	388 (58)	194 (61)	536 (63)	
M2	113 (17)	37 (12)	112 (13)	
Other (e.g., M3, ACA)	6 (0.9)	0 (0)	8 (0.9)	
ASPECTS	9 [7, 10]	9 [8, 10]	9 [8, 10]	2.9
Collaterals				6.1
Grade 0 - Absent collaterals	38 (5.8)	21 (6.7)	42 (5)	
Grade 1 - Occluded area filling <50%	241 (37)	115 (37)	293 (35)	
Grade 2 - Occluded area filling >50% but <100%	256 (39)	129 (41)	323 (39)	
Grade 3 - Occluded area filling 100%	115 (18)	47 (15)	176 (21)	
<i>Treatment factors</i>				
Treatment with intravenous alteplase	547 (78.9)	243 (73)	682 (77)	0.4
Time from admission ER (intervention center) to groin puncture	58 [35, 93]	60 [38, 86]	57 [35, 83]	8.9
Duration procedure	53 [35, 75]	56 [40, 79]	46 [32, 70]	7.4
General anesthetic management	165 (26)	115 (37)	248 (29)	5
Periprocedural heparin use	175 (25)	115 (35)	258 (29)	0
First pass success	180 (39)	128 (45)	411 (53)	20
<i>Post-procedural factors*</i>				
New ischemic stroke	13 (1.9)	3 (0.9)	14 (1.6)	0
Symptomatic intracranial hemorrhage	34 (4.9)	16 (4.8)	38 (4.3)	0
Pneumonia	69 (9.9)	32 (9.6)	76 (8.6)	0

Summary: Cohort characteristics of patients with successful (eTICI \geq 2B) and with excellent reperfusion (eTICI \geq 2C). Continuous data are presented as mean (SD) for normal distributed data or as median [IQR] for skewed data. Categorical data are presented as numbers (%).

Abbreviations: ACA, anterior cerebral artery; APT, antiplatelet therapy; ASPECTS, Alberta stroke program early computed tomography score; DOAC, direct oral anticoagulant; ER, emergency room; eTICI, extended thrombolysis in cerebral infarction including a 2C grade; ICA (T), internal carotid artery (terminus); INR, international normalized ratio; M(segment), middle cerebral artery; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale

*For the model with the modified NIHSS at 24-48 hour as outcome, post-procedural factors in the model were restricted to occurrence within 24 hours, which was only recorded for sICH (so new ischemic stroke and pneumonia were excluded).

3

1 MR CLEAN Registry Investigators – group authors**2 Executive committee**

3 Diederik W.J. Dippel¹;Aad van der Lugt²;Charles B.L.M. Majoe³;Yvo B.W.E.M.
4 Roos⁴;Robert J. van Oostenbrugge⁵;Wim H. van Zwam⁶;Jelis Boiten¹⁴;Jan Albert
5 Vos⁸

6 Study coordinators

7 Ivo G.H. Jansen³;Maxim J.H.L. Mulder^{1,2};Robert- Jan B. Goldhoorn^{5,6};Kars C.J.
8 Compagne²;Manon Kappelhof³;Josje Brouwer⁴;Sanne J. den Hartog^{1,2,40};Wouter H.
9 Hinsenvelde^{5,6};

10 Local principal investigators

11 Diederik W.J. Dippel¹;Bob Roozenbeek¹;Aad van der Lugt²;Adriaan C.G.M. van
12 Es²;Charles B.L.M. Majoe³;Yvo B.W.E.M. Roos⁴;Bart J. Emmer³;Jonathan M.
13 Coutinho⁴;Wouter J. Schonewille⁷;Jan Albert Vos⁸;Marieke J.H. Wermer⁹;Marianne
14 A.A. van Walderveen¹⁰;Julie Staals⁵;Robert J. van Oostenbrugge⁵;Wim H. van
15 Zwam⁶;Jeannette Hofmeijer¹¹;Jasper M. Martens¹²;Geert J. Lycklama à
16 Nijeholt¹³;Jelis Boiten¹⁴;Sebastiaan F. de Bruijn¹⁵;Lukas C. van Dijk¹⁶;H. Bart van der
17 Worp¹⁷;Rob H. Lo¹⁸;Ewoud J. van Dijk¹⁹;Hieronymus D. Boogaarts²⁰;J. de
18 Vries²²;Paul L.M. de Kort²¹;Julia van Tuijl²¹;Jo P. Peluso²⁶;Puck Fransen²²;Jan S.P.
19 van den Berg²²;Boudewijn A.A.M. van Hasselt²³;Leo A.M. Aerden²⁴;René J.
20 Dallinga²⁵;Maarten Uyttenboogaart²⁸;Omid Eschgi²⁹;Reinoud P.H. Bokkers²⁹;Tobien
21 H.C.M.L. Schreuder³⁰;Roel J.J. Heijboer³¹;Koos Keizer³²;Lonneke S.F. Yo³³;Heleen
22 M. den Hertog²²;Emiel J.C. Sturm³⁵;Paul J.A.M. Brouwers³⁴

23 Imaging assessment committee

24 Charles B.L.M. Majoe³(chair);Wim H. van Zwam⁶;Aad van der Lugt²;Geert J.
25 Lycklama à Nijeholt¹³;Marianne A.A. van Walderveen¹⁰;Marieke E.S.
26 Sprengers³;Sjoerd F.M. Jenniskens²⁷;René van den Berg³;Albert J. Yoo³⁸;Ludo F.M.
27 Beenen³;Alida A. Postma⁶;Stefan D. Roosendaal³;Bas F.W. van der Kallen¹³;Ido R.
28 van den Wijngaard¹³;Adriaan C.G.M. van Es²;Bart J. Emmer³;Jasper M. Martens¹²;
29 Lonneke S.F. Yo³³;Jan Albert Vos⁸;Joost Bot³⁶;Pieter-Jan van Doormaal²;Anton
30 Meijer²⁷;Elyas Ghariq¹³;Reinoud P.H. Bokkers²⁹;Marc P. van Proosdij³⁷;G. Menno
31 Krietemeijer³³;Jo P. Peluso²⁶;Hieronymus D. Boogaarts²⁰;Rob Lo¹⁸;Dick
32 Gerrits³⁵;Wouter Dinkelaar²Auke P.A. Appelman²⁹;Bas Hammer¹⁶;Sjoert
33 Pegge²⁷;Anouk van der Hoorn²⁹;Saman Vinke²⁰.

34 Writing committee

35 Diederik W.J. Dippel¹(chair);Aad van der Lugt²;Charles B.L.M. Majoe³;Yvo B.W.E.M.
36 Roos⁴;Robert J. van Oostenbrugge⁵;Wim H. van Zwam⁶;Geert J. Lycklama à
37 Nijeholt¹³;Jelis Boiten¹⁴;Jan Albert Vos⁸;Wouter J. Schonewille⁷;Jeannette
38 Hofmeijer¹¹;Jasper M. Martens¹²;H. Bart van der Worp¹⁷;Rob H. Lo¹⁸

39 Adverse event committee

40 Robert J. van Oostenbrugge⁵(chair);Jeannette Hofmeijer¹¹;H. Zwenneke Flach²³

41 Trial methodologist

42 Hester F. Lingsma⁴⁰

43 Research nurses / local trial coordinators

44 Naziha el Ghannouti¹;Martin Sterrenberg¹;Corina Puppels⁷;Wilma Pellikaan⁷;Rita
45 Sprengers⁴;Marjan Elfrink¹¹;Michelle Simons¹¹;Marjolein Vossers¹²;Joke de
46 Meris¹⁴;Tamara Vermeulen¹⁴;Annet Geerlings¹⁹;Gina van Vemde²²;Tiny
47 Simons³⁰;Cathelijn van Rijswijk²¹;Gert Messchendorp²⁸;Nynke Nicolaij²⁸;Hester
48 Bongenaar³²;Karin Bodde²⁴;Sandra Kleijn³⁴;Jasmijn Lodico³⁴;Hanneke
49 Droste³⁴;Maureen Wollaert⁵;Sabrina Verheesen⁵;D. Jeurissen⁵;Erna Bos⁹;Yvonne
50 Drabbe¹⁵;Michelle Sandiman¹⁵;Nicoline Aaldering¹¹;Berber Zweedijk¹⁷;Mostafa

1 Khalilzada¹⁵; Jocova Vervoort²¹; Eva Ponjee²²; Sharon Romviel¹⁹; Karin
2 Kanselaar¹⁹; Denn Barning¹⁰.

3 **PhD / Medical students:**

4 Esmee Venema⁴⁰; Vicky Chalos^{1,40}; Ralph R. Geuskens³; Tim van Straaten¹⁹; Saliha
5 Ergezen¹; Roger R.M. Harmsma¹; Daan Muijres¹; Anouk de Jong¹; Olvert A.
6 Berkhemer^{1,3,6}; Anna M.M. Boers^{3,39}; J. Huguet³; P.F.C. Groot³; Marieke A.
7 Mens³; Katinka R. van Kranendonk³; Kilian M. Treurniet³; Manon L. Tolhuisen^{3,39}; Heitor
8 Alves³; Annick J. Weterings³; Eleonora L.F. Kirkels³; Eva J.H.F. Voogd¹¹; Lieve M.
9 Schupp³; Sabine Collette^{28,29}; Adrien E.D. Groot⁴; Natalie E. LeCouffe⁴; Praneeta R.
10 Konduri³⁹; Haryadi Prasetya³⁹; Nerea Arrarte-Terreros³⁹; Lucas A. Ramos³⁹.

11 **List of affiliations**

12 Department of Neurology¹, Radiology², Public Health⁴⁰, Erasmus MC University
13 Medical Center;
14 Department of Radiology and Nuclear Medicine³, Neurology⁴, Biomedical
15 Engineering & Physics³⁹, Amsterdam UMC, University of Amsterdam, Amsterdam;
16 Department of Neurology⁵, Radiology⁶, Maastricht University Medical Center and
17 Cardiovascular Research Institute Maastricht (CARIM);
18 Department of Neurology⁷, Radiology⁸, Sint Antonius Hospital, Nieuwegein;
19 Department of Neurology⁹, Radiology¹⁰, Leiden University Medical Center;
20 Department of Neurology¹¹, Radiology¹², Rijnstate Hospital, Arnhem;
21 Department of Radiology¹³, Neurology¹⁴, Haaglanden MC, the Hague;
22 Department of Neurology¹⁵, Radiology¹⁶, HAGA Hospital, the Hague;
23 Department of Neurology¹⁷, Radiology¹⁸, University Medical Center Utrecht;
24 Department of Neurology¹⁹, Neurosurgery²⁰, Radiology²⁷, Radboud University
25 Medical Center, Nijmegen;
26 Department of Neurology²¹, Radiology²⁶, Elisabeth-TweeSteden ziekenhuis, Tilburg;
27 Department of Neurology²², Radiology²³, Isala Klinieken, Zwolle;
28 Department of Neurology²⁴, Radiology²⁵, Reinier de Graaf Gasthuis, Delft;
29 Department of Neurology²⁸, Radiology²⁹, University Medical Center Groningen;
30 Department of Neurology³⁰, Radiology³¹, Atrium Medical Center, Heerlen;
31 Department of Neurology³², Radiology³³, Catharina Hospital, Eindhoven;
32 Department of Neurology³⁴, Radiology³⁵, Medical Spectrum Twente, Enschede;
33 Department of Radiology³⁶, Amsterdam UMC, Vrije Universiteit van Amsterdam,
34 Amsterdam;
35 Department of Radiology³⁷, Noordwest Ziekenhuisgroep, Alkmaar;
36 Department of Radiology³⁸, Texas Stroke Institute, Texas, United States of America.